Navigation Links
Adeona Announces HartLab Expansion Into Microbiology Testing Services
Date:6/15/2010

op5='External Link';s.eVar3=s.prop5;s.prop15='96362114';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.adeonapharma.com/">www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding additional services making HartLab more competitive and HartLab's ability to develop and implement new culture techniques, immunoassays, and molecular methods for rapid detection and identification of common as well as unusual microbial pathogens. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure to expand the services currently offered or develop techniques and methods for rapid detection of microbial pathogens, a failure of additional services to result in the attraction of new customers, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
2. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
5. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
6. Perrigo Announces FDA Final Approval for Miconazole
7. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
8. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
9. GSK Announces Revised Product Labels for Serevent® and Advair®
10. US Oncology Announces iKnowMed(TM) Technology Platform
11. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/22/2014)... can be slowed and some of its symptoms ... in pomegranate. Also, the painful inflammation that ... disease could be reduced, according to the findings ... Huddersfield scientist Dr Olumayokun Olajide, who specialises in ... a new phase of research can explore the ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... The New Jersey Institute for Food, Nutrition ... of New Jersey has joined forces with ChopChop ... young people about health and nutrition in a new ... organizations. , The partnership will encompass quarterly custom editions ... video communications. ChopChop Magazine features plenty of child-friendly ...
(Date:8/22/2014)... very low levels of nicotine may reduce addiction ... a new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours ... types of cigarettes with markedly reduced nicotine levels. ... brandsall of which have very similar levels of ...
(Date:8/22/2014)... AcousticSheep LLC participated in one of the largest running ... Run – otherwise known as the “Happiest 5K on the Planet.” ... participants from Erie, surrounding areas, and even from as far away ... largest running events put on in Erie, PA yet – the ... the Planet.” The event took place on August 9, 2014 and ...
Breaking Medicine News(10 mins):Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 3
... getting action from Cardinal George and Public Official ... ... years ago, health care activist,Joe Novak -- during a private audience with ... of not-for-profit health,care systems, especially those that are Catholic., "Three years ...
... were implemented in poor countries, cases of stunting among under ... up to a quarter, according to new research being published ... Hygiene & Tropical Medicine, is one of the authors of ... and Child Undernutrition Series, which is being launched this week. ...
... 17 Fleishman-Hillard Inc. today pledged,$250,000 in global ... fight to reduce micronutrient deficiencies in developing countries.,Adopting ... Food and,Agribusiness Practice will provide communications strategy and ... of flour standard,practice around the world., One-third ...
... Pill timed to body,s rhythms, helps with morning joint ... A modified-release form of the steroid prednisone is ... joint stiffness in people with rheumatoid arthritis, a new ... Berlin studied 288 people with active rheumatoid arthritis. Half ...
... Texas In the last few years, personalized medicine ... customize treatment for a particular patient has emerged ... , Therapy guided by genetic testing has proven highly ... and lung cancer. Similar personalized therapies are on the ...
... School of Medicine discovered that proteins carrying chemical cargo ... tau protein, which plays an important role in Alzheimers ... cargo towards opposite ends of tracks called microtubules. Tau ... speed bump to regulate protein traffic, the group found. ...
Cached Medicine News:Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:Fleishman-Hillard Names FFI Global Cause for 2008 2Health News:Modified-Release Prednisone May Ease Rheumatoid Arthritis 2Health News:Discovery opens door to 'personalized' asthma therapy 2Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: